is this you? Claim your profile.
is this you? Claim your profile.
Senior Director, MD
HQ Phone:  (514) 340-9800
Direct Phone: (514) ***-****
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
6111 Royalmount Ave. Suite 100
Montreal, Quebec,H4P 2T4
Founded in 1983, Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 47th among Canada's top 100 R&D investors with $56 millio... more.
Country Medical Director
Teva Canada Innovation
Executive Vice President, Clinical Development
Lausanne University , Medical School
Lausanne University Medical School
Didier Reymond Didier Reymond Didier Reymond Didier brings more than 20 years of pharmaceutical industry experience to his role of Country Medical Director at Teva Canada Innovation. Originally from Switzerland, Didier moved to Canada in 1994 to pursue a clinical fellowship in pediatric infectious diseases at The Hospital for Sick Children, Toronto. There, he conducted bench research activities on Verotoxin-producing Escherichia coli before completing his fellowship at Montreal's Sainte-Justine Pediatric University Hospital. Prior to joining Teva Canada Innovation, Didier held a variety of roles in the pharmaceutical industry, beginning in 1997 as manager, then Associate Director, Scientific, Affairs at Merck Frosst Canada, Merck Vaccine Division, before joining the Oncology Business Unit at the Novartis Pharmaceuticals Canada in 2002 as Medical Advisor, then Senior Medical Advisor for solid tumors. He also brings experience in biotechnology, as he was appointed VP Medical and Clinical Affairs in 2007, then Executive VP, Clinical Development at Thallion Pharmaceuticals in Montreal. Recruited by Pharmascience Canada Inc. in 2013, as Senior Director, Medical Affairs, he led a group of 60 professionals involved in Medical Information, Pharmacovigilance, Clinical Operations, Medical Affairs (MSLs, Medical Advisors) and Biopharmaceutics, before moving to Teva Canada Innovation in late 2016. Didier graduated from Lausanne University Medical School, Switzerland in December 1987. He began his residency in pediatrics at the Lausanne University Hospital Centre before completing his training at the Pediatric University Hospital of Bern, Switzerland, and being board certified in 1994.
Dr. Didier Reymond
Executive Vice-President, Clinical Development firstname.lastname@example.org
Didier Reymond, MD
Executive Vice-President, Clinical Development Dr. Reymond leads clinical development for all phases ofThallion's clinicalprograms. Before Thallion, he was a Senior Medical Advisorwith Novartis Canada, leading the medical and clinical activities for solid tumors. Prior to that, Dr. Reymond was Associate Director, Scientific Affairs, for the Merck Vaccine Division, Merck Frosst Canada. He was responsible for Regulatory Affairs and Medical Affairs for all vaccines in Canada. Dr. Reymond graduated from Lausanne University, Medical School,before working in Pediatric Surgery and completing his residency in Pediatrics at the University Hospitals of Lausanne and Bern.Board certified in Pediatrics, Dr. Reymond pursued a Fellowship in Pediatric Infectious Diseases at The Hospital for Sick Children, Toronto, where he conducted research activities on Verotoxin-producing Escherichia coli. Dr. Reymond completed his fellowship program at the Hôpital Sainte-Justine, in Montreal, conducting pediatric clinical research focusing on oral antibiotics.
VP Clinical Development Thallion Pharmaceuticals
Didier Reymond, MD 514-228-3631 email@example.com